Preparation and application of high titer neutralizing antibody against varicella-herpes zoster virus / 中国生物制品学杂志

@#Objective To prepare high titer specific immune serum of varicella-herpes zoster virus(VZV)for the quality control of live attenuated varicella vaccine and live attenuated herpes zoster vaccine.MethodsMale rabbits were immunized with high purity recombinant gE glycoprotein combined with Freund's adjuvant,aluminum hydroxide adjuvant or MF59 adjuvant,2 rabbits in each group. On the 56th day after immunization,the maximum blood samples(heart or carotid artery)were collected from each rabbit to prepare serum,which was mixed with VZV for neutralization reaction,and then inoculated into a 6-well plate full of monolayer of MRC-5 human diploid cells. After incubation for 7 d,the number of plaques was counted and the neutralizing titer and virus neutralizing ability of immune serumwere determined. The serum with high neutralizing titer and virus neutralizing ability was selected for the identification test of live attenuated varicella vaccine and live attenuated herpes zoster vaccine VZV(Oka strain)working seed lot and the detection of exogenous virus factors.ResultsThe immune sera prepared by immunizing rabbits with various combinations of recombinant gE glycoprotein all showed neutralizing activity,among which the serum prepared by the combination of recombinant gE glycoprotein and Freund's adjuvant had the highest neutralizing titer of 1∶512 and the virus neutralizing ability of 240 000 PFU/mL;The prepared immune serum was usedfor the identification test of VZV(Oka strain)working seed lot and the detection of exogenous virus factors,of which all the results were in line with the requirements. Conclusion The recombinantgE glycoprotein could be used for the preparation of high titer neutralizing antibody against VZV,and the prepared high titer neutralizing antibody is suitable for thequality control of live attenuated varicella vaccine and live attenuated herpes zoster vaccine.

Effect of live attenuated varicella vaccine on tuberculin skin test / 中国热带医学

@#Abstract: Objective　This paper aims to explore the effect of live attenuated varicella vaccine on the sensitivity of tuberculin skin test(TST), and to provide reference for tuberculin skin test in the future. Methods　TST and emergency varicella vaccine were administered to students in grade one of a high school in Wuxi, Jiangsu province, who had both TB and varicella cases. Independent-samples t test was used to analyze the mean diameter of induration of TST in day 0, day 83 and day 195. The retrospective cohort study was used to analyze the effect of live attenuated varicella vaccine on TST. 　　Results　The mean induration diameter of 45 students who participated in three TST tests on day 0, day 83 and day 195 were analyzed by independent sample t test. On day 0, there was a difference in the mean diameter of TST induration between the unvaccinated and vaccinated groups(1.630±2.837 vs 5.818±4.530) (t=-3.692, P=0.001). On day 83, there was no difference in the mean diameter of TST induration between the two groups(0.001±0.001 vs 0.114±0.533) (t=-1.000, P=0.329). On day 195, there was a difference in the mean diameter of TST induration between the two groups(1.913±3.774 vs 5.023±5.126) (t=-2.309, P=0.026). Moreover, the retrospective cohort study showed that the mean diameter of TST induration changed more significantly after inoculation with varicella vaccine, RR=6.071, 95%CI (1.667-22.116), P<0.05; After inoculation with varicella vaccine, the mean diameter of TST test did not change significantly from day 0 to day 195 with no statistical significance RR=3.474, 95%CI (0.333-36.240), P>0.05. Conclusions　Live attenuated varicella vaccine may temporarily affect the sensitivity of tuberculin skin test.

Varicella Zoster Virus Spicific IgG Antibody Titer in Vaccinated and Infected Children

PURPOSE: Varicella is mild self limited disease with vesicular skin eruption but highly contagious and accompanied many complications. Especially, varicella is fatal in leukemic children and immunocompromised children. The live varicella zoster virus was first developed by Takahashi et al. in the 1974. This vaccine has now been licensed for general use in Europe and the United States as well as in Korea. The porpose of this study was to estimate the VZV IgG antibody titer and evaluate the efficacy of vaccination. METHODS: The VZV IgG antibody titers were estimated in 246 healthy children, 32 vacccinated and 43 naturally infected children by FAMA method. In some children of the these groups, VZV specific IgG subclasses were estimated by ELISA method. RESULTS: 1) In 246 healthy children, VZV IgG antibody titers were increased according to the age. 2) The positive rates VZV IgG antibody titer according to age were lowest at 1 to 2 years of the age with 22.4% and highest at 6 to 7 years of the age with 77.7%. 3) Comparing of the VZV IgG antibody titer in each groups according to the age, in children ranging from 1 year to 5 years of age, the VZV IgG antibody titer in vaccinated group was significantly increased compared with control group(p<0.05). In children over 6 years old, the VZV IgG antibody titer in disease groups was significantly increased compared with control group(p<0.05). 4) The VZV IgG antibody titers were decreased according to the duration after infection. 5) VZV specific IgG1 between control group and other groups were statistically different(p<0.05). IgG3 in infected group was significantly increased compared with control group(p<0.05). IgG4 in vaccinated group was significantly increased compared with control group(p<0.05). CONCLUSIONS: The live attenuated vaccine is recommended for preventing of varicella infection, but further evaluation and longterm follow up are necessary for protective efficacy of the VZV vaccine and about the VZV specific IgG subclass.

Immune response induced by live attenuated varicella vaccine(Biken@) in children with acute lymphoblastic leukemia

No abstract available.